What is Arvinas?
Arvinas is a pioneering biotechnology firm dedicated to the development of targeted protein degradation therapies. By leveraging its proprietary PROTAC platform, the company focuses on the discovery of innovative medicines designed to selectively degrade disease-causing proteins. This research-driven methodology targets complex conditions across oncology, neurology, and other serious disease areas, positioning Arvinas at the forefront of precision medicine and therapeutic innovation.
How much funding has Arvinas raised?
Arvinas has raised a total of $234.8M across 5 funding rounds:
Corporate Investment
$3.3M
Series A
$15M
Series B
$41.6M
Series C
$55M
Stock Offering
$120M
Corporate Investment (2013): $3.3M with participation from Connecticut Innovations and Connecticut Department of Economic and Community Development
Series A (2013): $15M led by Connecticut Innovations, Elm Street Ventures, 5AM Ventures, and Canaan Partners
Series B (2015): $41.6M supported by OrbiMed, Canaan Partners, RA Capital Management, New Leaf Venture Partners, and 5AM Ventures
Series C (2018): $55M featuring Canaan Partners, RA Capital Management, Sirona Capital, 5AM Ventures, New Leaf Venture Partners, OrbiMed, Deerfield Management, Hillhouse Capital, and Nextech Invest
Stock Issuance/Offering (2018): $120M backed by Undisclosed
Key Investors in Arvinas
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms to support innovation cycles.
Canaan Partners
Canaan is an early-stage venture capital firm that invests in technology and healthcare companies, backing founders from seed through growth stages in areas such as biopharma and digital health.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, utilizing its TechAtlas think tank to support strategic decisions.
What's next for Arvinas?
With the infusion of recent capital, Arvinas is well-positioned to accelerate its clinical programs and expand its research capabilities. The company's strategic roadmap focuses on validating its protein degradation technology through rigorous clinical trials and deepening its pipeline of candidates. By maintaining a focus on high-impact therapeutic areas, Arvinas aims to translate its scientific breakthroughs into viable commercial solutions, ultimately addressing significant unmet medical needs for patients worldwide.
See full Arvinas company page
